Sarepta Therapeutics (NASDAQ:SRPT) Raised to “Buy” at StockNews.com

Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Tuesday.

Several other equities analysts have also recently commented on the stock. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They issued a “buy” rating and a $165.00 price target for the company. Piper Sandler decreased their price target on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Barclays lowered their target price on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $205.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, November 7th. One analyst has rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $181.33.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $112.48 on Tuesday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 52 week low of $78.67 and a 52 week high of $173.25. The stock has a market capitalization of $10.74 billion, a PE ratio of 89.98 and a beta of 0.81. The firm has a 50 day moving average of $124.70 and a two-hundred day moving average of $132.66.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Michael Andrew Chambers bought 37,038 shares of the stock in a transaction on Friday, August 16th. The shares were bought at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Michael Andrew Chambers bought 37,038 shares of the stock in a transaction on Friday, August 16th. The shares were bought at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Institutional investors have recently modified their holdings of the business. Fifth Third Wealth Advisors LLC purchased a new stake in shares of Sarepta Therapeutics in the second quarter valued at approximately $607,000. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Sarepta Therapeutics in the second quarter valued at approximately $4,771,000. Securian Asset Management Inc. purchased a new stake in shares of Sarepta Therapeutics in the second quarter valued at approximately $1,187,000. Natixis Advisors LLC purchased a new stake in shares of Sarepta Therapeutics in the second quarter valued at approximately $1,918,000. Finally, Oppenheimer Asset Management Inc. boosted its stake in shares of Sarepta Therapeutics by 32.0% in the first quarter. Oppenheimer Asset Management Inc. now owns 3,604 shares of the biotechnology company’s stock valued at $467,000 after buying an additional 874 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.